Research Ethics Committee Reference Number	IRAS Number	Submission Type	Name of Trial	First Patient Recruited	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
17/NE/0234	228388	HRA Approval	KEYNOTE 629: A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)	No		19/07/2017	19/07/2017	29/08/2017	01/12/2017	13/12/2017	01/02/2018	Sponsor delay - considerable sponsor contract and costing delays	Sponsor
17/LO/1367	225049	HRA Approval	PS2: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NA?VE ADVANCED OR RECURRENT (STAGE IIIB NOT AMENABLE FOR MULTIMODALITY TREATMENT) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER WHO ARE DEEMED UNSUITABLE FOR PLATINUM-CONTAINING THERAPY	Yes	11/04/2018	24/05/2017	27/07/2017	19/09/2017	18/01/2018	22/01/2018	05/02/2018	Sponsor delays - awaiting submission of substantial amendment plus costing queries	Sponsor
16/NW/0718	204299	HRA Approval	Respiratory Distress Symptom Intervention (RDSI)	Yes	08/03/2018	22/09/2017	09/10/2017	15/06/2017	15/01/2018	15/01/2018	13/02/2018	Sponsor delay - sponsor took some time to greenlight CCC as a site	Sponsor
16/NE/0279	198051	HRA Approval	TIDAL: Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)	No		07/12/2017	21/12/2017	29/09/2016	14/02/2018	15/01/2018	15/02/2018	sub-contract delays from partner Trust	Neither
17/EE/0177	220722	HRA Approval	BOSTON: A Phase 3 Randomized, Controlled, Open-Label Study of Selinexor, Bortezomib, and Dexamethasone (SVD) Versus Bortezomib and Dexamethasone (VD) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)	No		31/10/2017	02/03/2018	24/07/2017	28/02/2018	13/03/2018	16/03/2018	sub-contract delays from partner Trust	Neither
18/EM/0005	236933	HRA Approval	AMG 20150136: An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices	Yes	29/06/2018	14/12/2017	15/12/2017	30/01/2018	20/02/2018	23/02/2018	16/03/2018	sub-contract delays from partner Trust	Neither
17/NW/0718	231114	HRA Approval	CA209-8A7: Early access to medicines scheme ? Nivolumab ? for gastric and Gastroesophageal Junction (GC/GEJ) Adenocarcinoma Observational Study	Yes	03/04/2018	12/03/2018	14/03/2018	22/12/2017	20/03/2018	21/03/2018	23/03/2018	No delays	Neither
17/SC/0228	219158	HRA Approval	JAVELIN H&N (B9991016): A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONT LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK	Yes	09/07/2018	01/11/2017	06/11/2017	24/07/2017	16/02/2018	22/02/2018	27/03/2018	complex financial and contract negotiations, internal capacity issues, delays in RTQA : Rare cancer.	Both

17/LO/2024	231946	HRA Approval	LUCY - Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations	No		31/08/2017	31/08/2017	14/02/2018				Awaiting patient pathway confirmation from PI - study still in set-up	NHS Provider
12/LO/0515	95626	HRA Approval	OPTIMA: Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis	No		07/09/2017	07/09/2017	03/08/2016				Awaiting study documentation from internal service departments - study still in set-up	NHS Provider
17/NW/0369	225797	HRA Approval	PRAN: PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, RANDOMIZED STUDY OF PRACINOSTAT IN COMBINATION WITH AZACITIDINE IN PATIENTS =18 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA UNFIT FOR STANDARD INDUCTION CHEMOTHERAPY	Yes	13/07/2018	01/07/2017	19/09/2017	15/09/2017	09/02/2018	14/02/2018	16/03/2018	Sub-contract delays from partner Trust	Neither
17/NW/0330	222996	HRA Approval	AGIOS: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation	No		12/09/2017	21/09/2017	16/10/2017	05/04/2018	05/07/2018		Internal capacity issues by support service: complicated contract & financial negotiations - study still in set-up	Both
17/LO/1875	219487	HRA Approval	RAMPART: Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage multi-centre randomised-controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.	No		10/11/2017	10/11/2017	03/11/2017				Project still in set-up. Initial delay in awaiting PI capacity - study still in set-up	NHS Provider
17/NW/0512	221775	HRA Approval	PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma	Yes	31/05/2018	05/10/2017	13/11/2017	08/11/2017	31/01/2018	11/01/2018	10/05/2018	sub-contract delays from partner Trust	Neither
17/LO/1869	230951	HRA Approval	TULIP :A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer	No		19/11/2017	19/11/2017					Awaiting patient pathway confirmation from PI - study still in set-up	NHS Provider
16/LO/0877	202257	HRA Approval	JAVELIN BLADDER: A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB* (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WHO COMPLETED FIRST-LINE CHEMOTHERAPY FOR UNRESECTABLE LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER	No		24/11/2017	29/11/2017	05/09/2016				PI withdrew from study	NHS Provider

17/EE/0034	218200	HRA Approval	ASTRAL 3: A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents	No		29/11/2017	05/12/2017	19/06/2017				sub-contract delays from partner Trust resulting in the Sponsor withdrawing the site	Neither
17/NE/0366	235534	HRA Approval	SEPCELL: A phase Ib/IIa, randomised, double blind, parallel group, placebo controlled, multicentre study to assess the safety and efficacy of Cx611 expanded allogeneic adipose-derived stem cells (eASCs) for the intravenous treatment of adult patients with a severe community-acquired bacterial pneumonia and admitted to the intensive care unit. SEPCELL study.	No		05/12/2017	15/12/2017					sub-contract delays from partner Trust	Neither
18/NE/0005	236687	HRA Approval	AMG 678: Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials	No		08/01/2018	08/01/2018	15/02/2018	01/06/2018	20/06/2018		Internal capacity issues by support service - study in set-up	NHS Provider
18/SC/0015	236685	HRA Approval	ACZ885: A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer(NSCLC)	No		21/12/2017	08/01/2018	23/02/2018	25/05/2018	12/06/2018		Complicated patient pathway and change over of nursing staff - study in set up	NHS Provider
14/SC/1346	151280	HRA Approval	National Lung Matrix Trial: Multi-drug,geneticmarker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer	No		12/01/2018	12/01/2018	15/07/2017				sub-contract delays from partner Trust - study in set-up	Neither
17/EM/0338	229242	HRA Approval	ABL001: A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors	No		28/07/2017	26/01/2018	31/01/2018				Study in set-up - not open	Neither
17/SC/0661	227234	HRA Approval	CYTOFLOC: Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge) for post chemo-radiotherapy surveillance in patients with oesophageal cancer ? a feasibility study	No		18/12/2017	26/01/2018	23/01/2018				Study in set-up - not open	Neither
17/NW/0634	209375	HRA Approval	COMICE: A randomized double blind placebo controlled Phase II clinical trial of Cediranib and Olaparib maintenance in advanced recurrent Cervical Cancer.	No		29/01/2018	29/01/2018					Study in set-up - not open	Neither
14/NE/1240	163350	HRA Approval	PFIZER B1371012: A RANDOMIZED, DOUBLE-BLIND PHASE 1B/2 STUDY OF PF-04449913 IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED INTERMEDIATE-2 OR HIGH-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA WITH 20-30% BLASTS AND MULTI-LINEAGE DYSPLASIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA	No		03/02/2018	03/02/2018	06/03/2018				Study in set-up - not open	Neither

18/LO/0651	240503	HRA Approval	BAYER 17403: A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy	No		08/02/2018	08/02/2018	13/06/2018				Study in set-up - not open	Neither
18/NW/0031	230387	HRA Approval	net-02: A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (NEC)	No		12/02/2018	12/02/2018	18/02/2018				Study in set-up - not open	Neither
17/YH/0187	218853	HRA Approval	PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma	No		22/02/2018	22/02/2018	11/10/2017				Study in set-up - not open	Neither
17/WA/0111	225522	HRA Approval	HATCY: A Phase III, multicenter, randomised controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy (HATCY study)	No		25/09/2017	02/03/2018					Study in set-up - not open	Neither
18/LO/0352	237528	HRA Approval	CA017-063: A Randomized, Global, Open-Label Study of Nivolumab in Combination with BMS-986205 vs Standard of Care Extreme chemotherapy in first-line recurrent/metastatic squamous cell carcinoma of the head and neck	No		21/02/2018	08/03/2018					WITHDRAWN BY SPONSOR	Neither
15/SC/0103	154496	HRA Approval	SCALOP 2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer	No		14/02/2018	31/03/2018	26/07/2016				Study in set-up - not open	Neither
17/LO/1149	220763	HRA Approval	SHIRE: A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients	No		01/08/2017	01/08/2017	12/09/2017	07/02/2018	23/02/2018	05/04/2018	Sub-contracting delays with partner Trust	Neither
16/WM/0501	185601	HRA Approval	WISTERIA: A Phase I trial of WEE1 inhibition with Chemotherapy and Radiotherapy as adjuvant treatment, and a Window of Opportunity trial with Cisplatin in Patients with Head and Neck Cancer	No		08/02/2018	08/02/2018	28/02/2017	11/04/2018	29/03/2018	19/04/2018	complicated phase I pathway, complex contracting and finance negotiations	Both

14/EM/1172	146009	HRA Approval	Cambridge Brain Mets Trial 1: A proof? of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low?-dose, targeted radiotherapy	No		30/06/2016	13/11/2017	26/07/2016	20/05/2016	13/06/2017	27/04/2018	Awaited the Phase I element of the study to finish before entering the study at next Phase: Sponsor put study on temporary halt for several months.	Both
17/LO/1289	226881	HRA Approval	UNITY UTX TGR 205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin?s Lymphoma.	No		16/11/2017	20/12/2017	17/10/2017	21/05/2018	17/05/2018	01/06/2018	Sub-contracting delays with partner Trust	Neither
17/WS/0180	225790	HRA Approval	OREO: A Phase 111b, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy (OReO)	No		13/09/2017	12/10/2017	02/02/2018	20/04/2018	22/05/2018	08/06/2018	Complex and protracted contract and financial negotiations : staff capacity issues	Sponsor
16/LO/2195	219516	HRA Approval	TRITON 2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency	Yes	27/04/2018	31/05/2017	30/09/2017	28/03/2017	01/02/2018	12/02/2018	23/03/2018	Complex financial and contract negotiations, internal capacity issues to support	Both
17/EM/0120	222298	HRA Approval	TRITON 3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician?s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency	Yes	26/04/2018	31/05/2017	30/09/2017	30/06/2017	01/02/2018	12/02/2018	23/03/2018	Complex financial and contract negotiations, internal capacity issues to support	Both
17/LO/0497	220229	HRA Approval	IMMUNOCORE 202: A PHASE II RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF IMCGP100 COMPARED WITH INVESTIGATOR?S CHOICE IN HLA-A*0201 POSITIVE PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED UVEAL MELANOMA	Yes	11/06/2018	26/06/2017	05/09/2017	14/11/2017	07/02/2018	12/02/2018	28/03/2018	Costing queries, internal capacity issues & sub-contract delays from partner Trust	Both
16/LO/0422	198606	HRA Approval	SIERRA-2: A Phase I Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone in Subjects with Advanced Cancer	No		21/09/2017	27/11/2017	23/05/2016				Study still in set-up - Not open	Neither
16/LO/0423	198451	HRA Approval	SIERRA-1: A Phase I trial of SRA737 (a CHK1 inhibitor) administered orally in subjects with advanced cancer	No		21/09/2017	24/11/2017	19/05/2016				Study still in set-up - Not open	Neither
17/EM/0166	222665	HRA Approval	AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)	No		29/03/2018	29/03/2018	30/06/2017				Study still in set-up - Not open	Neither
14/WM/1170	161147	HRA Approval	COMPARE: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer	No		22/01/2016	22/07/2017	23/05/2016	19/06/2018	05/06/2018		Study in set-up - Delays with partner Trust 2 site opening	NHS Provider

17/LO/1727	215490	HRA Approval	MUK nine b: OPTIMUM. A phase II study evaluating optimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia.	No		15/08/2017	15/08/2017	30/03/2017				Study in set-up: Dependent on MUK 9B opening, 9B has subcontracting delays with partner Trust	Neither
15/WS/0011	122822	HRA Approval	BALLAD: A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma (IRCI-002)	No		31/10/2017	31/10/2017	29/04/2016	26/02/2018	08/02/2018		Study still in set-up - internal capacity issues	NHS Provider